Therapeutics
What physicians prescribe, and what the evidence supports.
Therapeutics · Metabolic Health
Tirzepatide earns its first outcomes label
FDA approved tirzepatide to reduce MACE in adults with type 2 diabetes at cardiovascular risk. The claim rests on SURPASS-CVOT against dulaglutide, an active comparator, with an 8% relative reduction.
Therapeutics · Metabolic Health
The Lp(a) drug moved the number, not the outcome
Novartis and Ionis reported topline Phase III results from Lp(a)HORIZON on September 4: 8,323 patients with elevated Lp(a) and established cardiovascular disease on guideline-directed therapy.
Therapeutics · Metabolic Health
Semaglutide, started late, extended life in mice
Female mice started daily semaglutide at 20 months, roughly a human mid-60s, and stayed on it for life. Median lifespan rose from 742 to 834 days, about 12%.
The Sunday edition.
The week in longevity medicine, every Sunday.
Free, delivered by Substack. Unsubscribe any time.